Silvan Tuerkcan
Stock Analyst at JMP Securities
(2.32)
# 2,518
Out of 4,944 analysts
166
Total ratings
42.33%
Success rate
-2.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Reiterates: Market Outperform | $50 | $38.49 | +29.90% | 23 | Jul 29, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $70 → $12 | $2.97 | +304.04% | 6 | Jul 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $57.33 | +50.01% | 16 | Jun 27, 2025 | |
| NUVB Nuvation Bio | Reiterates: Market Outperform | $6 | $2.61 | +129.89% | 3 | Jun 25, 2025 | |
| SLDB Solid Biosciences | Reiterates: Market Outperform | $15 | $6.68 | +124.55% | 3 | Jun 6, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $5 → $6 | $3.03 | +98.02% | 13 | May 29, 2025 | |
| PRME Prime Medicine | Maintains: Market Outperform | $10 → $6 | $3.81 | +57.48% | 3 | May 20, 2025 | |
| BNTC Benitec Biopharma | Reiterates: Market Outperform | $20 | $12.51 | +59.87% | 12 | May 15, 2025 | |
| FHTX Foghorn Therapeutics | Reiterates: Market Outperform | $9 | $5.17 | +74.08% | 3 | May 15, 2025 | |
| VOR Vor Biopharma | Downgrades: Market Perform | $6 | $2.02 | +197.03% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $3.68 | +389.13% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $20 | $6.49 | +208.17% | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.31 | +1,197.71% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $6.61 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $0.70 | +471.43% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $3.42 | +514.04% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.66 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $2.79 | +115.05% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $178.51 | +56.85% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $10.24 | +75.78% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.00 | - | 10 | Jan 19, 2023 |
Exelixis
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $38.49
Upside: +29.90%
Jasper Therapeutics
Jul 8, 2025
Maintains: Market Outperform
Price Target: $70 → $12
Current: $2.97
Upside: +304.04%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $57.33
Upside: +50.01%
Nuvation Bio
Jun 25, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $2.61
Upside: +129.89%
Solid Biosciences
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $6.68
Upside: +124.55%
Taysha Gene Therapies
May 29, 2025
Maintains: Market Outperform
Price Target: $5 → $6
Current: $3.03
Upside: +98.02%
Prime Medicine
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.81
Upside: +57.48%
Benitec Biopharma
May 15, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $12.51
Upside: +59.87%
Foghorn Therapeutics
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $5.17
Upside: +74.08%
Vor Biopharma
May 9, 2025
Downgrades: Market Perform
Price Target: $6
Current: $2.02
Upside: +197.03%
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.68
Upside: +389.13%
Apr 21, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $6.49
Upside: +208.17%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.31
Upside: +1,197.71%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $6.61
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.70
Upside: +471.43%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $3.42
Upside: +514.04%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.66
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $2.79
Upside: +115.05%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $178.51
Upside: +56.85%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $10.24
Upside: +75.78%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $11.00
Upside: -